Showing results (2081-2090 of 3,796) with videos related to
Sort By:
Pageof 380
Oncoimmunology|December 20, 2013
REG3β contributes to the immunosuppressive microenvironment of pancreatic cancerEmma Folch-PuyOncoimmunology|November 2, 2013
Biological insights into BRAFV600 mutations in melanoma patient: Not mere therapeutic targetsGiuseppina Improta, Giuseppe Pelosi, Elena Tamborini, et al.Oncoimmunology|November 2, 2013
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsJames P Stevenson, Hedy L Kindler, Emmanouil Papasavvas, et al.Oncoimmunology|March 22, 2021
BAFF receptor antibody for mantle cell lymphoma therapyKeman Zhang, Nand K Roy, Yorleny Vicioso, et al.Oncoimmunology|March 24, 2021
Stromal-like Wilms tumor cells induce human Natural Killer cell degranulation and display immunomodulatory properties towards NK cellsClaudia Cantoni, Martina Serra, Erica Parisi, et al.Oncoimmunology|March 24, 2021
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patientsJana Rakova, Iva Truxova, Peter Holicek, et al.Oncoimmunology|January 10, 2022
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma modelAki Furusawa, Ryuhei Okada, Fuyuki Inagaki, et al.Oncoimmunology|December 3, 2021
Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axisMark A J M Hendriks, Isabel Britsch, Xiurong Ke, et al.Oncoimmunology|December 3, 2021
Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patientsGuido Kroemer, Oliver KeppOncoimmunology|December 3, 2021
CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturationRyan M Reyes, Chenghao Zhang, Yilun Deng, et al.Pageof 380